Connor, Clark & Lunn Investment Management Ltd. Nurix Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.8 Billion
- Q1 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 237,104 shares of NRIX stock, worth $4.95 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
237,104
Previous 185,070
28.12%
Holding current value
$4.95 Million
Previous $1.91 Million
82.56%
% of portfolio
0.02%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding NRIX
# of Institutions
144Shares Held
50.2MCall Options Held
30.3KPut Options Held
22.7K-
Black Rock Inc. New York, NY4.58MShares$95.6 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.48MShares$93.6 Million2.6% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$81 Million0.72% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$62.6 Million1.46% of portfolio
-
State Street Corp Boston, MA2.73MShares$57 Million0.0% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $984M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...